Analysis Group Inc.

Boston, MA, United States

Analysis Group Inc.

Boston, MA, United States

Time filter

Source Type

News Article | May 18, 2017
Site: www.prnewswire.com

The analysis showed that introduction of ARYMO ER may be associated with fewer abuse-related emergency department visits, outpatient visits, hospitalizations, substance abuse treatments, injection related diseases and deaths. While the model incorporates actual medical and drug claims for diagnosed abusers, as well as information on ARYMO ER's physical and chemical properties based on its in vitro Category 1 abuse-deterrent data, the true extent of the potential for harm reduction will not be known until ARYMO ER has been marketed for a period of time and data are generated on reduction of misuse and abuse in the real world. "Model results present evidence that abuse-deterrent formulations of extended-release morphine, such as ARYMO ER, may be associated with fewer abuse-related emergency department visits, outpatient visits, hospitalizations, substance abuse treatments, injection-related diseases and deaths," said Alan G. White, Ph.D., managing principal of the Analysis Group and author of the data presented. "Abuse-deterrent opioids are prescribed by physicians to help manage their patients' painful conditions and may lower the risk of misuse/abuse, potentially leading to reductions in abuse-related healthcare utilization." The poster titled, "A harm reduction model to quantify potential misuse/abuse reduction and misuse/abuse-related events avoided from extended-release abuse deterrent opioids," was presented by Dr. White today. Egalet also presented four other posters today. About The American Pain Society Based in Chicago, the American Pain Society (APS) is a multidisciplinary community that brings together a diverse group of scientists, clinicians and other professionals to increase the knowledge of pain and transform public policy and clinical practice to reduce pain-related suffering.  APS is the professional home for investigators involved in all aspects of pain research including basic, translational, clinical and health services research to obtain the support and inspiration they need to flourish professionally.  APS strongly advocates expansion of high quality pain research to help advance science to achieve effective and responsible pain relief.  For more information on APS, visit www.americanpainsociety.org. About Egalet Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use only –CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX (ketorolac tromethamine) Nasal Spray. Using Guardian Technology Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com. For additional information on Egalet, please visit egalet.com. ARYMO ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ARYMO ER is contraindicated in patients with:  significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days, known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity (e.g., anaphylaxis) to morphine. : ARYMO ER contains morphine, a Schedule II controlled substance. As an opioid, ARYMO ER exposes its users to the risks of addiction, abuse, and misuse. As extended-release products such as ARYMO ER deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of morphine present. : Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status. Carbon dioxide (CO ) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of ARYMO ER, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with and following dosage increases with ARYMO ER. To reduce the risk of respiratory depression, proper dosing and titration of ARYMO ER are essential. Overestimating the ARYMO ER dose when converting patients from another opioid product can result in a fatal overdose with the first dose. Accidental ingestion of even one dose of ARYMO ER, especially by children, can result in respiratory depression and death due to an overdose of morphine. : Prolonged use of ARYMO ER during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available. Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants : Profound sedation, respiratory depression, coma, and death may result from the concomitant use of ARYMO ER with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics. Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients : The use of ARYMO ER in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated. Patients with Chronic Pulmonary Disease: ARYMO ER-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of ARYMO ER. Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients. Monitor such patients closely, particularly when initiating and titrating ARYMO ER and when ARYMO ER is given concomitantly with other drugs that depress respiration. Alternatively, consider the use of non-opioid analgesics in these patients. : Monoamine oxidase inhibitors (MAOIs) may potentiate the effects of morphine, including respiratory depression, coma, and confusion. ARYMO ER should not be used in patients taking MAOIs or within 14 days of stopping such treatment. : Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. : ARYMO ER may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension after initiating or titrating the dose of ARYMO ER. In patients with circulatory shock, ARYMO ER may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use ARYMO ER in patients with circulatory shock. Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness : In patients who may be susceptible to the intracranial effects of CO retention (e.g., those with evidence of increased intracranial pressure or brain tumors), ARYMO ER may reduce respiratory drive, and the resultant CO retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with ARYMO ER. Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of ARYMO ER in patients with impaired consciousness or coma. Difficulty in Swallowing and Risk for Obstruction in Patients at Risk for a Small Gastrointestinal Lumen : Moistened ARYMO ER tablets may become sticky leading to difficulty in swallowing the tablets. Patients could experience choking, gagging, regurgitation and tablets stuck in the throat. Instruct patients not to pre-soak, lick, or otherwise wet ARYMO ER tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in the mouth. Tablet stickiness and swelling may also predispose patients to intestinal obstruction and exacerbation of diverticulitis. Patients with underlying GI disorders such as esophageal cancer or colon cancer with a small gastrointestinal lumen are at greater risk of developing these complications. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying GI disorders resulting in a small gastrointestinal lumen. Risks of Use in Patients with Gastrointestinal Conditions : ARYMO ER is contraindicated in patients with gastrointestinal obstruction, including paralytic ileus. The morphine in ARYMO ER may cause spasm of the sphincter of Oddi. Opioids may cause increases in the serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms. Increased Risk of Seizures in Patients with Seizure Disorders : The morphine in ARYMO ER may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during ARYMO ER therapy. : Avoid the use of mixed agonist/antagonist (i.e., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who have received or are receiving a course of therapy with a full opioid agonist analgesic, including ARYMO ER. In these patients, mixed agonists/antagonist and partial agonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms. When discontinuing ARYMO ER, gradually taper the dose. Do not abruptly discontinue ARYMO ER. : ARYMO ER may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of ARYMO ER and know how they will react to the medication. In clinical trials, the most common adverse reactions with morphine sulfate extended-release formulations were constipation, dizziness, sedation, nausea, vomiting, sweating, dysphoria, and euphoric mood. : The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. : May reduce the analgesic effect of ARYMO ER and/or precipitate withdrawal symptoms; avoid concomitant use. : Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. : The concomitant use of cimetidine can potentiate morphine effects and increase risk of hypotension, respiratory depression, profound sedation, coma, and death. : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. : The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. : The concomitant use of P-gp inhibitors can increase the exposure to morphine by about two-fold and can increase risk of hypotension, respiratory depression, profound sedation, coma, and death. : The safety and effectiveness in pediatric patients below the age of 18 have not been established. : The pharmacokinetics of ARYMO ER have not been studied in elderly patients. Elderly patients (aged 65 years or older) may have increased sensitivity to morphine. : Morphine pharmacokinetics have been reported to be significantly altered in patients with cirrhosis. Start these patients with a lower than usual dosage of ARYMO ER and titrate slowly while monitoring for signs of respiratory depression, sedation, and hypotension. : Morphine pharmacokinetics are altered in patients with renal failure. Start these patients with a lower than usual dosage of ARYMO ER and titrate slowly while monitoring for signs of respiratory depression, sedation, and hypotension. Acute overdosage with morphine can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations. Safe Harbor Statements included in this press release that are not historical in nature and contain the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "look forward to" and other similar expressions are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include expectations in 2017 of seeing continued growth with the dedicated SPRIX salesforce, the potential addition of new OXAYDO dosage strengths and the introduction of ARYMO ER to healthcare providers, are based on management's current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet's clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet's ability to obtain regulatory approval of its product candidates and the labeling claims that Egalet believes are necessary or desirable for successful commercialization of its products and product candidates; Egalet's ability to maintain the intellectual property position of its products and product candidates; Egalet's ability to identify and reliance upon qualified third parties to manufacture its products; Egalet's ability to commercialize its products; and to do so successfully; the costs of commercialization activities, including marketing, sales and distribution; the size and growth potential of the markets for Egalet's products and product candidates, and Egalet's ability to service those markets; Egalet's ability to obtain reimbursement and third-party payor contracts for its products; Egalet's ability to service its debt obligations; Egalet's ability to raise additional funds to execute its business plan and growth strategy on terms acceptable to Egalet, if at all; Egalet's ability to find and hire qualified sales professionals; the rate and degree of receptivity in the marketplace and among physicians to Egalet's products; the success of products which compete with Egalet's that are or become available; general market conditions; and the Risk Factors set forth in Egalet's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in other filings Egalet makes with the SEC from time to time.  In addition, the forward-looking statements included in this press release represent Egalet's views only as of the date hereof. Egalet anticipates that subsequent events and developments may cause its views to change. While Egalet may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/egalet-announces-results-of-arymo-er-harm-reduction-modeling-analysis-300460326.html


News Article | May 17, 2017
Site: www.businesswire.com

BOSTON--(BUSINESS WIRE)--Dr. Howard Birnbaum and Paul Greenberg, both of Analysis Group, have co-edited a book entitled Decision Making in a World of Comparative Effectiveness Research that is intended to serve as a guide for real-world analysis. Published by Springer, the book is a practical guide to decision making using CER—that is, observational data in real-world settings. CER considers the effectiveness of comparative evidence from many data sources, including electronic medical records, administrative claims, patient surveys, and clinical trials. This type of evidence can yield new insights into the effectiveness of alternative medical treatments. Unlike other books about CER that have focused on methodologies, Decision Making in a World of Comparative Effectiveness Research includes in-depth analysis from prominent stakeholders across the medical field, including senior industry executives, key opinion leaders, accomplished researchers, and attorneys. Geared toward global CER decision makers within the life sciences industry and government, the book covers, among other topics, the future of CER for evidence developers; evolving stakeholder considerations; and emerging challenges, methods, and applications of CER. Decision Making in a World of Comparative Effectiveness Research is now available for purchase on the Springer and Amazon websites. Analysis Group is one of the largest private economics consulting firms, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise.


Rene Befurt, Vice President with Analysis Group, Inc. to Speak at The Knowledge Group’s Trademark and False Advertising Litigation Webinar Rene Befurt, Vice President with Analysis Group, Inc. to Speak at The Knowledge Group’s Trademark and False Advertising Litigation: Significant Issues & Updates to Level Up Your Game plan. New York, NY, May 20, 2017 --( For further details, please visit: https://knowgp.org/2r42kZs About Rene Befurt Dr. Befurt specializes in applying his expertise in marketing research methodologies to both litigation and strategy case work, focusing on how to best isolate the impact of product or service characteristics on consumer behavior, including consumer choice. His recent engagements in litigation work include surveys on evaluating the perceived health benefit of consumer goods; assessing how much an electronic communication device’s features contribute to the purchase of such a device in a patent litigation; and various matters examining false advertising allegations and potential consumer confusion. Dr. Befurt has also worked on matters testing the salience and comprehension of disclaimers and disclosures. Dr. Befurt has supported leading marketing authorities in designing and implementing a number of survey approaches and has also served as an expert. About Analysis Group, Inc. Analysis Group is one of the largest private economics consulting firms, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise. Abstract The Lanham Act clearly prohibits a number of activities which include trademark infringement, dilution, and false advertising. Traditionally, trademarks and trade names abide by the same general laws to minimize the negative effects arising from false and misleading advertising. In this live webcast a seasoned panel of thought leaders, professionals and counsel assembled by The Knowledge Group will provide the audience with an in-depth analysis of the significant issues and recent updates with regard to Trademark and False Advertising Litigation. Speakers will present best practices and practical tips to avoid unnecessary risks and pitfalls. Key topics include: • Trademark and False Advertising Litigation – An Overview • The Lanham Act • The Effects of Misinformation • Recent Court Decisions • Scope and Limitations • Risks and Legal Challenges About The Knowledge Group/The Knowledge Congress Live Webcast Series The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/ New York, NY, May 20, 2017 --( PR.com )-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Rene Befurt, Vice President with Analysis Group, Inc. will speak at The Knowledge Group’s webcast entitled: “Trademark and False Advertising Litigation: Significant Issues & Updates to Level Up Your Game plan.” This event is scheduled for June 22, 2017 from 12:00 pm to 1:30 pm (ET).For further details, please visit: https://knowgp.org/2r42kZsAbout Rene BefurtDr. Befurt specializes in applying his expertise in marketing research methodologies to both litigation and strategy case work, focusing on how to best isolate the impact of product or service characteristics on consumer behavior, including consumer choice. His recent engagements in litigation work include surveys on evaluating the perceived health benefit of consumer goods; assessing how much an electronic communication device’s features contribute to the purchase of such a device in a patent litigation; and various matters examining false advertising allegations and potential consumer confusion. Dr. Befurt has also worked on matters testing the salience and comprehension of disclaimers and disclosures. Dr. Befurt has supported leading marketing authorities in designing and implementing a number of survey approaches and has also served as an expert.About Analysis Group, Inc.Analysis Group is one of the largest private economics consulting firms, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise.AbstractThe Lanham Act clearly prohibits a number of activities which include trademark infringement, dilution, and false advertising. Traditionally, trademarks and trade names abide by the same general laws to minimize the negative effects arising from false and misleading advertising.In this live webcast a seasoned panel of thought leaders, professionals and counsel assembled by The Knowledge Group will provide the audience with an in-depth analysis of the significant issues and recent updates with regard to Trademark and False Advertising Litigation. Speakers will present best practices and practical tips to avoid unnecessary risks and pitfalls.Key topics include:• Trademark and False Advertising Litigation – An Overview• The Lanham Act• The Effects of Misinformation• Recent Court Decisions• Scope and Limitations• Risks and Legal ChallengesAbout The Knowledge Group/The Knowledge Congress Live Webcast SeriesThe Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/


News Article | May 22, 2017
Site: www.businesswire.com

BOSTON--(BUSINESS WIRE)--Analysis Group, one of the largest private economics consulting firms, announces the promotion of 41 consultants and welcomes seven new affiliates to the firm. “ We are pleased to recognize the outstanding efforts of our consultants, as well as the addition of such impressive new affiliates, all of whom are recognized leaders in their respective fields,” said CEO and Chairman Martha S. Samuelson. Shannon W. Anderson, a professor of management at the UC Davis Graduate School of Management, conducts research on the design of cost accounting systems and on how firms use management control practices to mitigate risk and facilitate collaboration in inter-firm transactions. This research includes performance measurement, incentive contracting, supply chain contracting, and operations management. Professor Anderson uses empirical analysis of firm-level accounting and operational data to test economic theories about firm performance. She also has experience designing and administering surveys and analyzing survey data. Her published work has employed data from many industries, including automotive, electronics manufacturing, office furniture manufacturing, commercial airlines, consumer retail, coal extraction, transportation, and warehousing and distribution. Professor Anderson coauthored the award-winning book Implementing Management Innovations and the textbook Fundamentals of Cost Accounting (now in its 5th edition). Her research has been published in leading research journals, including The Accounting Review, Management Science, and Contemporary Accounting Research, and has been funded by the American Institute of Certified Public Accountants, the Institute of Internal Auditors, and the National Science Foundation, among others. Jacques Crémer, research faculty at the Toulouse School of Economics, is an expert in industrial organization with a focus on competition, contracting, auction and planning theory, and the economics of organization. His recent research examines these issues with applications to the economics of two-sided platforms, industries with network effects, and the Internet. Professor Crémer has testified before the European Commission in relation to the AOL-Time Warner merger, and consulted to clients including Microsoft, Google, Sucre Saint Louis, Intel, GTE, and Time Warner. He has published on such topics as the consequences of mergers on competition and policy, the costs and benefits of vertical integration, and the value of switching costs. Professor Crémer’s work has appeared in peer-reviewed journals such as American Economic Review and The Quarterly Journal of Economics. He is a Fellow of the European Economic Association and the Econometric Society. From 2011 to 2014, Professor Crémer was the Scientific Director at the Toulouse School of Economics (TSE), and was previously Director of Institut d’Economie Industrielle (IDEI), a TSE research institute focused on partnerships with government and industry. Randal S. Milch, a Distinguished Fellow at the New York University School of Law's Center on Law and Security, has extensive expertise in corporate governance, cybersecurity, and data privacy issues. Over his 21 years at Verizon Communications Inc. (where he was EVP and General Counsel to the Chair and CEO), Mr. Milch was deeply involved in the deregulation and transformation of the telecommunications industry. He oversaw the public policy, legal, regulatory, government affairs, and security groups at Verizon, testified before committees of Congress, and organized and led significant public policy campaigns relating to state and federal legislation and transactional approvals. He also managed national security matters, set cyber-policy, and served as the senior cleared executive. Mr. Milch is currently chair of the Board of Equal Justice Works and serves as a trustee of New York University School of Law. He is a former partner in the Washington, D.C. office of Donovan, Leisure, Newton & Irvine. Michael D. Mitzenmacher, the Thomas J. Watson, Sr. Professor of Computer Science at Harvard University’s John A. Paulson School of Engineering and Applied Sciences, researches the design and analysis of algorithms, networks and data transmission, computer security, information theory, and use of encryption. He has consulted to numerous technology companies and research laboratories, including Adverplex (Cogolabs), Akamai, AT&T, Digital Fountain, eHarmony, Fluent Mobile (Fiksu), Google, Huawei, ITA Software, JobSync, Microsoft, Mitsubishi Research Laboratories, and Yahoo. In addition, he has served as an expert witness on software and intellectual property issues in several cases, including testimony in multiple trials. Professor Mitzenmacher has authored or coauthored over 200 conference and journal publications on various topics, including algorithms for the Internet; efficient hash-based data structures; erasure; and error-correcting codes, power laws, and compression. His work on low-density parity-check codes shared the 2002 IEEE Information Theory Society Best Paper Award and won the 2009 ACM SIGCOMM Test of Time Award. Prior to joining Harvard, he worked as a research scientist at Digital Systems Research Center on information retrieval on the Web, erasure codes, error-correcting codes, on-line algorithms, and load balancing. Nathan Novemsky, a professor of marketing in the Yale School of Management and a professor of psychology at Yale University, is an expert in the psychology of judgment and decision-making, an area that overlaps heavily with behavioral economics and consumer behavior. His area of specialization is examining how consumers are affected by information in their environments, including how particular types of information impact their choices and judgments. He is a member of the Yale Center for Customer Insights, and has consulted on numerous legal cases (e.g., deceptive advertising, defamation) related to how individuals interpret information they see in the media and other contexts. Professor Novemsky has published widely on the topics of judgment and decision-making, and regularly teaches these concepts to executives around the world. Paul Oyer, the Fred H. Merrill Professor of Economics at the Stanford Graduate School of Business, is an expert in the economics of organizations and human resource practices. In the field of personnel economics, he has undertaken several studies on how organizations pay and provide incentives for their workers. He has also examined how salespeople and executives react to incentive systems, and why some firms use broad-based stock option programs. In addition, he has conducted research on how firms have adjusted their human resource practices in response to legal barriers for dismissing workers. His current research focuses on how companies identify and recruit workers in highly-skilled and competitive labor markets. His research has been published in numerous peer-reviewed journals, including The Quarterly Journal of Economics, American Economic Review, and The Journal of Finance. Professor Oyer is a research associate with the National Bureau of Economic Research and the editor-in-chief of the Journal of Labor Economics. Prior to joining Stanford, he was on the faculty of the Kellogg School of Management at Northwestern University. He also previously worked for Booz, Allen & Hamilton; 3Com Corporation; and ASK Computer Systems. John E. Ware, the Professor and Chief of Outcomes Measurement Science in the Department of Quantitative Health Sciences at the University of Massachusetts Medical School, is an internationally recognized leader in measuring Patient Reported Outcomes (PRO). His substantial contributions to the outcomes research field have focused on developing, standardizing, and applying health metrics to assess patient reported outcomes. His work has led to the development of a set of standardized, generic PRO measures, including the SF-36® Health Survey, as well as disease-specific measures such as the Headache Impact Test (HIT-6™) survey. Professor Ware frequently provides guidance on evidence support for PRO labeling, and he has been the invited expert for testimony on PRO topics at hearings held by the U.S. Food and Drug Administration. His current research interests also include applying modern psychometric methods to construct more actionable measures, including the first disease-specific quality-of-life (QOL) impact scale standardized across conditions and normed in representative chronically-ill populations. Professor Ware is a member of the National Academy of Medicine (formerly the Institute of Medicine). The firm promoted one consultant to managing principal. Richard A. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has provided economic analyses in numerous antitrust matters involving questions of market power, pricing, and market exclusion and foreclosure in a variety of industries, with a focus on healthcare. He has also provided analyses and expert testimony on behalf of clients in the healthcare industry on litigation and government investigations involving allegations of improper promotion and kickback payments. Dr. Mortimer's experience includes leading analyses of large data sets to assess questions of market definition, class certification, liability, and damages. In addition to work in litigation, Dr. Mortimer has undertaken research in the area of health care policy, and he has authored several public policy studies related to pharmaceutical and general health care legislation. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and Journal of Medical Economics. In Boston, Ryan Booth specializes in applying microeconomic theory, antitrust economics, and econometric methods to a range of issues that include assessing the competitive effects of firm conduct, the implications of mergers and acquisitions on consumer welfare, and the effects of government policy on consumer and firm behavior. Emily Cotton has extensive experience conducting complex quantitative and qualitative analyses of data in both mergers and litigation matters, including antitrust, bankruptcy, class certification, intellectual property, securities, survey design, tax, and transfer-pricing matters. Chris Feige specializes in the areas of finance, securities, and financial systems. He has developed complex valuation models, including discounted cash flow models, and has analyzed asset-backed securities and credit ratings in support of expert testimony in a number of bankruptcy and damages matters. Lauren Hunt specializes in providing analyses in finance cases involving complex securities, including mortgage-backed securities (MBS). She has supported experts in numerous litigations involving class action claims, allegations of violations of Sections 10b-5 and 11, and damages claims relating to the underwriting of mortgage loans. Kenneth Weinstein specializes in the application of quantitative methods to real-world problems involving decision-making, strategy, risk management, and litigation. He has managed the analysis of large transaction-level and claims databases, helped clients mitigate the risks associated with distributing controlled substances, and developed flexible damages models for negotiating high-stakes settlements. Hongbo Yang, a specialist in health economics and outcomes research, has directed and conducted numerous studies in a variety of therapeutic areas, including autoimmune diseases, infectious diseases, diabetes, blood disorders, oncology, women's health, and central nervous system diseases. She has led the submission of economic models to multiple health technology assessment agencies (HTAs), including NICE, CADTH, INESSS, and OHTAC. In Denver, Carletta Wong has a decade of experience applying economic consulting expertise to a variety of litigation matters involving securities, accounting, antitrust, corporate governance, off-label pharmaceutical marketing, and intellectual property and trade secrets. In Los Angeles, Keith Betts specializes in the application of advanced biostatistics techniques in the field of health economics and outcomes research. He has broad experience developing research strategies in a range of disease areas, including immunology, hematology, oncology, psychiatry, and virology. In Menlo Park, Anjali D. Oza specializes in the application of economic, statistical, and market research methods to litigation and strategy matters. She is an expert in designing and evaluating qualitative and quantitative surveys, including conjoint analysis and experiments. In Montréal, François Laliberté applies his distinctive competencies in biostatistics and economics to the field of health outcomes research. He has investigated different facets of health research including safety, cost of illness, resource utilization, adherence to therapies, cost-effectiveness, and treatment outcomes. Markus von Wartburg specializes in the application of econometric methods and microeconomic theory to complex problems in antitrust and competition, commercial litigation, media and telecommunications, finance, and intellectual property. In New York City, Duncan Fung specializes in commercial litigation matters involving securities, finance, valuation, corporate governance, and statistics. He has supported clients on consulting engagements involving structured finance products, hedge funds, market microstructure, employee stock options, equity financing trades, and liquidity in money markets. Stephanie Lee’s litigation and advisory experience includes analyses of municipal bonds and interest rate swaps, auction-rate securities, student loan asset-backed securities, residential mortgage-backed securities, hedge funds, and mutual funds. She has provided testimony to Financial Industry Regulatory Authority (FINRA) arbitration panels. In Washington, D.C., F. Michael Nolan has extensive experience applying microeconomic, financial, and accounting principles to complex business litigation matters involving automobiles, agricultural products, high-technology products, telecommunications, consumer electronics, medical equipment, and pharmaceuticals. Federico Temerlin specializes in the application of economics, finance, and statistical theory to the analysis of complex legal and business disputes. He has evaluated issues related to misrepresentation of information, damages modeling, business and asset valuation, complex financial structures, tax shelters, and corporate restructurings. The firm promoted 25 consultants to manager or senior economist. In Beijing: Simeng Han. In Boston: Anya Blank, Konstantin A. Danilov, Katie Franklin, Olga Korolev, Elizabeth Milsark, Jeremy Smith, Yan Song, Todor Stoyanov, David Toniatti, and Kristof Zetenyi. In Chicago: Mark Berberian and David Smith. In Dallas: Jeffrey Hulbert. In Denver: Stacey Chan. In Los Angeles: Maral DerSarkissian, Anne LaRue, Jinlin Song, Nathan Trujillo, and Joel Wiles. In Menlo Park: Daniel Deisenroth and Ruoding Tan. In Montréal: Dominic Pilon. In San Francisco: Tracy Danner. In Washington, D.C.: Anna Gumen. Analysis Group is one of the largest private economics consulting firms, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies worldwide. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise.


News Article | May 24, 2017
Site: www.eurekalert.org

KNOXVILLE, Tenn. - Memorial Day Weekend is heralded the nation over as the unofficial start to summer. Schools have dismissed for the academic year, or soon will. The weather has warmed, and outdoor recreation will soon peak. So, it's timely that a new, detailed study conducted by the University of Tennessee Institute of Agriculture has quantified the economic value of outdoor recreation, at least along the Tennessee Valley Authority's managed river system. The study, which was performed by a team of scientists from the UTIA departments of Forestry, Wildlife and Fisheries and Agricultural and Resource Economics, determined that the combination of aquatic recreation and waterfront property along the Tennessee Valley Authority's managed river system creates $11.9 billion of annual economic impact to the region -- the equivalent of $1 million per shoreline mile. In addition, the TVA-supported study found that TVA's 49 reservoirs support about 130,000 jobs annually. To reach these conclusions, UTIA researchers conducted in-depth surveys of visitors and property owners along three of TVA's 49 reservoirs -- Norris, Watts Bar and Chickamauga -- during Summer 2016. Those reservoirs were chosen to represent urban, rural and tributary reservoir classifications. From that cross-section, the survey data was then extrapolated to cover the entire river system. Scientists involved included Neelam Poudyal, an assistant professor of natural resource policy, and Burton English, Kim Jensen and Jamey Menard, all members of the UTIA Agri-Industry Modeling & Analysis Group (AIM-AG). AIM-AG is well known for performing economic impact evaluations for industries and government entities. Several UT graduate and undergraduate students also participated by conducting a mail survey of shoreline property owners as well as on-site surveys of reservoir visitors at public access points, including fishing piers, swimming areas, boat launches and commercial marinas. Responses from more than 1,100 recreational users were included in the study. "Since its beginnings 84 years ago, TVA's mission has been to improve the lives of those in the Valley, and our integrated river management system is one of the cornerstones of our efforts," said Mike Skaggs, TVA Executive Vice President of Operations. Skaggs, other TVA officials, and representatives from UTIA unveiled the study results earlier this month as the agency kicked off a series of visits with civic officials and media from communities along the river system. "The UTIA study clearly establishes a strong link between the recreational opportunities our reservoirs create and improving the economic opportunities for the nine million people we serve every day," Skaggs added. First developed to provide flood control, navigation and hydroelectric power, TVA's integrated development plan for the Tennessee River and its tributaries also provides boating, swimming, and fishing enthusiasts their choice of unique destinations across all seven states in its service area. Poudyal, who specializes in the study of the human dimensions of natural resource policy, notes that TVA reservoirs provide tremendous outdoor opportunities to local and non-local visitors and visitors find their overall experiences highly satisfying. "Considering all the amenities that TVA reservoirs offer, the level of satisfaction among recreational users was relatively high - 75 percent," he said. Based on expenditures, the UTIA economists agreed. English remarked, "The study found that recreational visitors to the TVA reservoir system generate an average annual economic impact of $11.9 billion as well as more than 130,000 local jobs, $4.45 billion in labor income and $916 million in state and local taxes." English further remarked that the study did not take every economic impact into consideration. For example, the UTIA study did not consider the additional economic impacts created by non-aquatic based recreation (camping, hunting and hiking), and it did not address the additional economic benefits created by TVA's core missions of flood control or river transportation. The positive contributions of recreation along the river system are in addition to TVA's more formal economic development activities and partnerships, which contributed to more than $8 billion of capital investment and the creation or retention of more than 72,000 jobs in the Tennessee Valley last year alone. The Tennessee Valley Authority is a corporate agency of the United States that provides electricity for business customers and local power distributors serving more than 9 million people in parts of seven southeastern states. TVA receives no taxpayer funding, deriving virtually all of its revenues from sales of electricity. In addition to operating and investing its revenues in its electric system, TVA provides flood control, navigation and land management for the Tennessee River system and assists local power companies and state and local governments with economic development and job creation. Through its mission of research, teaching and extension, the University of Tennessee Institute of Agriculture touches lives and provides Real. Life. Solutions. ag.tennessee.edu.


Receive press releases from The Knowledge Group: By Email Carla Mulhern, Managing Principal with Analysis Group to Speak at The Knowledge Group’s ITC Section 337 Investigations: Your Thorough Guide for 2017 & Beyond New York, NY, April 19, 2017 --( For further details, please visit: https://knowgp.org/2nXuBhS About Carla Mulhern Ms. Mulhern specializes in the application of economic principles to issues arising in complex business litigation. She has provided expert testimony in numerous patent infringement cases, including those involving Section 337 violations at the International Trade Commission (ITC). Before the ITC, Ms. Mulhern has testified on economic issues such as domestic industry, remedy, bonding, commercial success, and public interest. In addition to her ITC experience, she has served as an expert witness on damages issues in commercial litigation matters providing testimony in various district and state courts. Ms. Mulhern’s intellectual property damages experience includes cases involving allegations of patent, copyright, and trademark infringement, as well as misappropriation of trade secrets. Her work spans a variety of industries, including pharmaceuticals, medical devices, automotive, entertainment, consumer products, computer hardware and software, semiconductors, and telecommunications. In non-litigation matters, Ms. Mulhern has assisted clients in valuing intellectual property and other business assets in the context of strategic alliances and joint ventures. She is a member of the American Economic Association and the Licensing Executives Society, and is a frequent writer and speaker on issues related to intellectual property valuation and damages assessment. About Analysis Group Analysis Group is one of the largest private economics consulting firms in North America, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise. Abstract Section 337 of the Tariff Act of 1930 prohibits unfair methods of competition and practices in import trade, particularly the importation or sale of infringing goods in the United States. U.S. International Trade Commission (ITC) Section 337 investigations involve high stakes for both patent holders and parties accused of importing infringing products. Complex and challenging ITC investigations demand a multi-disciplined approach that involves knowledge of intellectual property litigation and international trade and policy. It is important for businesses and their counsel to understand the unique procedural framework of ITC Section 337 investigations. The Knowledge Group has assembled a panel of key thought leaders and practitioners to discuss ITC Section 337 investigations and offer guidance to navigate the complexities of Section 337 proceedings. In a two-hour live webcast, the speakers will discuss: - Overview of Section 337 - ITC Section 337 Investigations Framework - Asserting Section 337 Claims - Issues and Challenges in a Section 337 Investigation - Recent Filing Trends at the ITC - Recent ITC Case Decisions About The Knowledge Group/The Knowledge Congress Live Webcast Series The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/ New York, NY, April 19, 2017 --( PR.com )-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Carla Mulhern, Managing Principal with Analysis Group will speak at The Knowledge Group’s webcast entitled: “ITC Section 337 Investigations: Your Thorough Guide for 2017 & Beyond.” This event is scheduled for May 3, 2017 from 12:00pm to 2:00pm (ET).For further details, please visit: https://knowgp.org/2nXuBhSAbout Carla MulhernMs. Mulhern specializes in the application of economic principles to issues arising in complex business litigation. She has provided expert testimony in numerous patent infringement cases, including those involving Section 337 violations at the International Trade Commission (ITC). Before the ITC, Ms. Mulhern has testified on economic issues such as domestic industry, remedy, bonding, commercial success, and public interest. In addition to her ITC experience, she has served as an expert witness on damages issues in commercial litigation matters providing testimony in various district and state courts. Ms. Mulhern’s intellectual property damages experience includes cases involving allegations of patent, copyright, and trademark infringement, as well as misappropriation of trade secrets. Her work spans a variety of industries, including pharmaceuticals, medical devices, automotive, entertainment, consumer products, computer hardware and software, semiconductors, and telecommunications. In non-litigation matters, Ms. Mulhern has assisted clients in valuing intellectual property and other business assets in the context of strategic alliances and joint ventures. She is a member of the American Economic Association and the Licensing Executives Society, and is a frequent writer and speaker on issues related to intellectual property valuation and damages assessment.About Analysis GroupAnalysis Group is one of the largest private economics consulting firms in North America, with more than 700 professionals across 11 offices in the United States, Canada, and China. Since 1981, we have provided expertise in economics, finance, health care analytics, and strategy to top law firms, Fortune 500 companies, and government agencies. Our internal experts, together with our network of affiliated experts from academia, industry, and government, offer our clients exceptional depth of expertise.AbstractSection 337 of the Tariff Act of 1930 prohibits unfair methods of competition and practices in import trade, particularly the importation or sale of infringing goods in the United States. U.S. International Trade Commission (ITC) Section 337 investigations involve high stakes for both patent holders and parties accused of importing infringing products. Complex and challenging ITC investigations demand a multi-disciplined approach that involves knowledge of intellectual property litigation and international trade and policy. It is important for businesses and their counsel to understand the unique procedural framework of ITC Section 337 investigations.The Knowledge Group has assembled a panel of key thought leaders and practitioners to discuss ITC Section 337 investigations and offer guidance to navigate the complexities of Section 337 proceedings.In a two-hour live webcast, the speakers will discuss:- Overview of Section 337- ITC Section 337 Investigations Framework- Asserting Section 337 Claims- Issues and Challenges in a Section 337 Investigation- Recent Filing Trends at the ITC- Recent ITC Case DecisionsAbout The Knowledge Group/The Knowledge Congress Live Webcast SeriesThe Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org/ Click here to view the company profile of The Knowledge Group Click here to view the list of recent Press Releases from The Knowledge Group


Hunting is a major threat to wildlife particularly in tropical regions, but a systematic large-scale estimate of hunting-induced declines of animal numbers was lacking so far. A study published in Science on April 14 fills this gap. An international team of ecologists and environmental scientists found that bird and mammal populations were reduced within 7 and 40 km of hunters' access points, such as roads and settlements. Within these impact zones, mammal populations declined on average by 83% and bird populations by 58%. Additionally, the team found that commercial hunting had a higher impact than hunting for family food, and that hunting pressure was higher in areas with better accessibility to major towns where wild meat could be traded. The impact of hunting was found to be larger than the team expected. 'Thanks to this study, we estimate that only 17 percent of the original mammal abundance and 42 percent of the birds remain in hunted areas.' The researchers synthesised 176 studies to quantify hunting-induced declines of mammal and bird populations across the tropics of Central and South America, Africa and Asia. The study was led by Ana Benítez-López, who works at the department of Environmental Science at Radboud University in Nijmegen, the Netherlands. She cooperated with researchers from the Netherlands Environmental Assessment Agency (PBL), the universities of Wageningen and Utrecht in the Netherlands and a colleague from the School of Life Sciences, University of Sussex. 'There are several drivers of animal decline in tropical landscapes: habitat destruction, overhunting, fragmentation etcetera. While deforestation and habitat loss can be monitored using remote sensing, hunting can only be tracked on the ground. We wanted to find a systematic and consistent way to estimate the impact of hunting across the tropics. As a starting point, we used the hypothesis that humans gather resources in a circle around their village and in the proximity of roads. As such, hunting pressure is higher in the proximity of villages and other access points. From there the densities of species increase up to a distance where no effect of hunting is observed. We called this species depletion distances which we quantified in our analysis. This allowed us to map hunting-induced declines across the tropics for the first time,' Benítez-López explains. Not only the big cuddly species The main novelty of the current study is that it combined the evidence across many local studies, thus for the first time providing an overarching picture of the magnitude of the impact across a large number of species. The study takes all animals into account - not only the big cuddly species, but birds and rodents as well. Benítez-López explains the difference in impact between birds and mammals: 'Mammals are more sought after because they're bigger and provide more food. They are worth a longer trip. The bigger the mammal, the further a hunter would walk to catch it.' With increasing wild meat demand for rural and urban supply, hunters have harvested the larger species almost to extinction in the proximity of the villages and they must travel further distances to hunt. Besides, for commercially interesting species such as elephants and gorillas, hunting distances are much larger because the returns are higher. Another interesting finding of this study is that mammal populations have also been reduced by hunting even within protected areas. 'Strategies to sustainably manage wild meat hunting in both protected and unprotected tropical ecosystems are urgently needed to avoid further defaunation,' she says. 'This includes monitoring hunting activities by increasing anti-poaching patrols and controlling overexploitation via law enforcement'. A. Benitez-Lopez*, R. Alkemade2,3, A. M. Schipper2, D. J. Ingram4, P. A. Verweij5, J. A. J. Eikelboom2,5,6, M. A. J. Huijbregts1, 2 . 2017. The impact of hunting on tropical mammal and bird populations. Science (accepted), April 14 2017 DOI: 10.1126/science.aaj1891 1Department of Environmental Science, Institute for Wetland and Water Research, Radboud University,The Netherlands2PBL, Netherlands Environmental Assessment Agency, The Hague, The Netherlands. 3Environmental Systems Analysis Group, Wageningen University & Research, The Netherlands 4School of Life Sciences, University of Sussex, UK. 5Energy and Resources group, Copernicus Institute of Sustainable Development, Utrecht University, 6Resource Ecology Group, Wageningen University & Research The Netherlands

Loading Analysis Group Inc. collaborators
Loading Analysis Group Inc. collaborators